A practical reference on Synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-04 and is reviewed periodically as new material appears.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Other experiments show that a single miRNA may repress the production of hundreds of proteins, but that this repression often is relatively mild (less than 2-fold). The effects of miRNA dysregulation of gene expression seem to be important in cancer. For instance, in gastrointestinal cancers, nine miRNAs have been identified as epigenetically altered and effective in down regulating DNA repair enzymes. The let-7 family of miRNAs provides a well-characterized example of miRNA dysregulation in cancer. Let-7-5p isoforms are among the most consistently downregulated miRNAs in hepatocellular carcinoma and several other malignancies, and their suppression is associated with upregulation of oncogenes including c-MYC, CDK6, and the RNA-binding protein LIN28B, as well as efflux ATP-binding cassette (ABC) transporters that govern multidrug resistance. Loss of let-7 activity establishes a self-reinforcing circuit, as LIN28B actively suppresses let-7 maturation, further sustaining the expression of let-7 target genes and contributing to a chemotherapy-resistant phenotype. Reintroduction of depleted tumor-suppressive miRNAs has therefore been explored as a strategy to restore natural post-transcriptional regulation of oncogenic targets and resensitize resistant cancer cells to treatment.
Oxytocin and vasopressin receptors are present in many other brain regions, including the amygdala, brainstem, and septum, as well as most nuclei in the hypothalamus. Because so much vasopressin and oxytocin are released at this site, studies of the supraoptic nucleus have made an important contribution to understanding how release from dendrites is regulated, and in understanding its physiological significance. Studies have demonstrated that secretin helps to facilitate dendritic oxytocin release in the SON, and that secretin administration into the SON enhances social recognition in rodents. This enhanced social capability appears to be working through secretin's effects on oxytocin neurons in the SON, as blocking oxytocin receptors in this region blocks social recognition.
"National" organizations operating outside their original homelands. WOSM's conference admitted and recognised the exile Russian Scouts as the "Representatives of Russian Scouting in Foreign Countries" on 30 August 1922 and the Armenian Scouts in France were recognized as a "National Movement on Foreign Soil" on 30 April 1929. Small, non-voting associations. The International Boy Scouts of the Canal Zone, a group in Panama with Scouts that claimed British and not Panamanian nationality was originally placed under the Boy Scouts of America's Canal Zone Council but, in 1947, was transferred under WOSM's bureau. The group had over 900 members in 1957 and existed as a directly registered group until the late 60s. The Boy Scouts of the United Nations began in 1945 and for years there was an active Boy Scouts of the United Nations with several troops at Parkway Village in New York City but only 14 members in 1959. Both the International Boy Scouts of the Canal Zone and the Boy Scouts of United Nations have long since disbanded. Directly registered "mixed-nationality Troops" were registered after discussions concerning such troops took place at WOSM's 3rd conference in 1924 at which WOSM's bureau was authorized to directly register such groups. It seems that the discussion at WOSM's 1924 conference was, at least in part, prompted by a letter to Baden-Powell from the Scoutmaster of one such troop in Yokohama, Japan. Janning's troop became the first troop directly registered by WOSM's bureau.
Alternatively, they can be conducted on well-sheltered shallow waters nearshore of a body of water (inshore aquaculture), where the cultivated species are subjected to relatively more naturalistic environments; or on fenced/enclosed sections of open water away from the shore (offshore aquaculture), where the species are either cultured in cages, racks or bags and are exposed to more diverse natural conditions such as water currents (such as ocean currents), diel vertical migration and nutrient cycles. According to the Food and Agriculture Organization (FAO), aquaculture "is understood to mean the farming of aquatic organisms including fish, molluscs, crustaceans and aquatic plants. Farming implies some form of intervention in the rearing process to enhance production, such as regular stocking, feeding, protection from predators, etc. Farming also implies individual or corporate ownership of the stock being cultivated." The reported output from global aquaculture operations in 2019 was over 120 million tonnes valued at US$274 billion, by 2022, it had risen to 130.9 million tonnes, valued at USD 312.8 billion. However, there are issues with the reliability of the reported figures. Further, in current aquaculture practice, products from several kilograms of wild fish are used to produce one kilogram of a piscivorous fish like salmon. Plant and insect-based feeds are also being developed to help reduce wild fish being used for aquaculture feed.
Sources: en.wikipedia.org
==== MeSH D06.472.910 – thymus hormones ==== MeSH D06.472.910.750 – thymic factor, circulating MeSH D06.472.910.800 – thymopoietins MeSH D06.472.910.800.850 – thymopentin MeSH D06.472.910.850 – thymosin
== Global statistics == As of 2014, there were 281 marketed orphan drugs and more than 400 orphan-designated drugs in clinical trials. More than 60% of orphan drugs were biologics. The U.S. dominated development of orphan drugs, with more than 300 trials, followed by Europe. Cancer treatment was the indication in more than 30% of orphan drug trials.
In hepatocellular carcinoma models, O-GlcNAc is associated with activating phosphorylation of HDAC1, which in turn regulates expression of the cell cycle regulator p21Waf1/Cip1 and cell motility regulator E-cadherin. OGT has been found to stabilize SREBP-1 and activate lipogenesis in breast cancer cell lines. This stabilization was dependent on the proteasome and AMPK. OGT knockdown resulted in decreased nuclear SREBP-1, but proteasomal inhibition with MG132 blocked this effect. OGT knockdown also increased the interaction between SREBP-1 and the E3 ubiquitin ligase FBW7. AMPK is activated by T172 phosphorylation upon OGT knockdown, and AMPK phosphorylates SREBP-1 S372 to inhibit its cleavage and maturation. OGT knockdown had a diminished effect on SREBP-1 levels in AMPK-null cell lines. In a mouse model, OGT knockdown inhibited tumor growth but SREBP-1 overexpression partly rescued this effect. These results contrast from those of a previous study which found that OGT knockdown/inhibition inhibited AMPK T172 phosphorylation and increased lipogenesis. In breast and prostate cancer cell lines, high levels of OGT and O-GlcNAc have been associated both in vitro and in vivo with processes associated with disease progression, e.g., angiogenesis, invasion, and metastasis. OGT knockdown or inhibition was found to downregulate the transcription factor FoxM1 and upregulate the cell-cycle inhibitor p27Kip1 (which is regulated by FoxM1-dependent expression of the E3 ubiquitin ligase component Skp2), causing G1 cell cycle arrest.
== Side effects == Since SNRIs and SSRIs act in similar ways to elevate serotonin levels, they share many side effects, though to varying degrees. Some common side effects include nausea, dry mouth, dizziness, sweating, increased blood pressure, loss of appetite, headache, increase in suicidal thoughts, and sexual dysfunction. Elevation of norepinephrine levels can sometimes cause anxiety, mildly elevated pulse, and elevated blood pressure. However, norepinephrine-selective antidepressants, such as reboxetine and desipramine, have successfully treated anxiety disorders. People at risk for hypertension and heart disease should monitor their blood pressure.
=== Legal status === In September 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zynlonta, intended for the treatment of adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The applicant for this medicinal product is ADC Therapeutics (NL) B.V. Loncastuximab tesirine was approved for medical use in the European Union in December 2022.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.